Correction to: Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis

Dee Lin¹ · Philippe Thompson-Leduc² · Isabelle Ghelerter² · Ha Nguyen³ · Marie-Hélène Lafeuille² · Carmela Benson¹ · Panagiotis Mavros¹ · Patrick Lefebvre²

Published online: 4 August 2021
© Springer Nature Switzerland AG 2021

Correction to: CNS Drugs (2021) 35(5):469–481
<https://doi.org/10.1007/s40263-021-00815-y>

The article ‘Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis’ by Dee Lin, Philippe Thompson-Leduc, Isabelle Ghelerter, Ha Nguyen, Marie-Hélène Lafeuille, Carmela Benson, Panagiotis Mavros and Patrick Lefebvre, was originally published electronically on SpringerLink on 28 April 2021.

After publication in volume 35, issue 5, pages 469–481, the authors highlighted that two of the references cited in the Supplementary Information were incorrect. This error has been rectified and a new corrected version of the Supplementary Information has been uploaded with the manuscript on SpringerLink.

The original article has been corrected.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s40263-021-00850-9>.

The original article can be found online at <https://doi.org/10.1007/s40263-021-00815-y>.

✉ Philippe Thompson-Leduc
Philippe.Thompson-Leduc@analysisgroup.com

¹ Janssen Scientific Affairs, LLC, Titusville, NJ, USA

² Analysis Group, Inc., Montreal, QC, Canada

³ Analysis Group, Inc, Boston, MA, USA